Literature DB >> 25500120

Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease.

Linda Mah1, Malcolm A Binns2, David C Steffens3.   

Abstract

OBJECTIVE: To test the hypothesis that anxiety in amnestic mild cognitive impairment (aMCI) increases rates of conversion to Alzheimer disease (AD) and to identify potential neural mechanisms underlying such an association.
METHODS: Participants (N = 376) with aMCI from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were studied over a median period of 36 months. A Cox proportional-hazards model was used to assess the association between anxiety severity ratings on the Neuropsychiatric Inventory Questionnaire and AD risk. Other variables were depression, memory loss, and MRI-derived AD-related regions of interest (ROIs), including hippocampal, amygdalar, entorhinal cortical (EC) volumes, and EC thickness, In addition, a linear regression model was used to determine the effect of anxiety in aMCI on rates of atrophy within ROIs.
RESULTS: Anxiety severity increased rate of aMCI conversion to AD, after controlling for depression and cognitive decline. The association between anxiety and AD remained significant even with inclusion of ROI baseline values or atrophy rates as explanatory variables. Further, anxiety status predicted greater rates of decrease in EC volume. An association between anxiety and EC thickness missed significance.
CONCLUSION: Anxiety symptoms in aMCI predict conversion to AD, over and beyond the effects of depression, memory loss, or atrophy within AD neuroimaging biomarkers. These findings, together with the greater EC atrophy rate predicted by anxiety, are compatible with the hypothesis that anxiety is not a prodromal noncognitive feature of AD but may accelerate decline toward AD through direct or indirect effects on EC.
Copyright © 2015 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; MRI biomarker; amygdala; anxiety; depression; entorhinal cortex; mild cognitive impairment; neuropsychiatric symptoms

Mesh:

Year:  2014        PMID: 25500120      PMCID: PMC4390420          DOI: 10.1016/j.jagp.2014.10.005

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  57 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

Review 2.  Time-dependent covariates in the Cox proportional-hazards regression model.

Authors:  L D Fisher; D Y Lin
Journal:  Annu Rev Public Health       Date:  1999       Impact factor: 21.981

3.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

4.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Authors:  R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

Review 5.  Stress and the individual. Mechanisms leading to disease.

Authors:  B S McEwen; E Stellar
Journal:  Arch Intern Med       Date:  1993-09-27

6.  Cortisol levels during human aging predict hippocampal atrophy and memory deficits.

Authors:  S J Lupien; M de Leon; S de Santi; A Convit; C Tarshish; N P Nair; M Thakur; B S McEwen; R L Hauger; M J Meaney
Journal:  Nat Neurosci       Date:  1998-05       Impact factor: 24.884

7.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.

Authors:  D I Kaufer; J L Cummings; P Ketchel; V Smith; A MacMillan; T Shelley; O L Lopez; S T DeKosky
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2000       Impact factor: 2.198

Review 8.  The Alzheimer's disease neuroimaging initiative.

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Neuroimaging Clin N Am       Date:  2005-11       Impact factor: 2.264

9.  Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

Authors:  Constantine G Lyketsos; Oscar Lopez; Beverly Jones; Annette L Fitzpatrick; John Breitner; Steven DeKosky
Journal:  JAMA       Date:  2002-09-25       Impact factor: 56.272

10.  Perspectives on depression, mild cognitive impairment, and cognitive decline.

Authors:  David C Steffens; Emeline Otey; George S Alexopoulos; Meryl A Butters; Bruce Cuthbert; Mary Ganguli; Yonas E Geda; Hugh C Hendrie; Ranga R Krishnan; Anand Kumar; Oscar L Lopez; Constantine G Lyketsos; Benjamin T Mast; John C Morris; Maria C Norton; Guerry M Peavy; Ronald C Petersen; Charles F Reynolds; Stephen Salloway; Kathleen A Welsh-Bohmer; Jerome Yesavage
Journal:  Arch Gen Psychiatry       Date:  2006-02
View more
  35 in total

1.  Methodology and preliminary results from the neurobiology of late-life depression study.

Authors:  David C Steffens; Kevin J Manning; Rong Wu; James J Grady; Richard H Fortinsky; Howard A Tennen
Journal:  Int Psychogeriatr       Date:  2015-09-01       Impact factor: 3.878

2.  Long-term and short-term predictors of worries about getting Alzheimer's disease.

Authors:  Stephen J Cutler; Corina Brăgaru
Journal:  Eur J Ageing       Date:  2015-07-17

3.  Temporal dynamics of cognitive performance and anxiety across older adulthood.

Authors:  Andrew J Petkus; Chandra A Reynolds; Julie Loebach Wetherell; William S Kremen; Margaret Gatz
Journal:  Psychol Aging       Date:  2017-03-23

Review 4.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

5.  Automated segmentation of medial temporal lobe subregions on in vivo T1-weighted MRI in early stages of Alzheimer's disease.

Authors:  Long Xie; Laura E M Wisse; John Pluta; Robin de Flores; Virgine Piskin; Jose V Manjón; Hongzhi Wang; Sandhitsu R Das; Song-Lin Ding; David A Wolk; Paul A Yushkevich
Journal:  Hum Brain Mapp       Date:  2019-04-29       Impact factor: 5.038

6.  Appetite and Weight Loss Symptoms in Late-Life Depression Predict Dementia Outcomes.

Authors:  Sayoni Saha; Daniel J Hatch; Kathleen M Hayden; David C Steffens; Guy G Potter
Journal:  Am J Geriatr Psychiatry       Date:  2016-06-06       Impact factor: 4.105

7.  Hallucinations and Delusions Signal Alzheimer's Associated Cognitive Dysfunction More Strongly Compared to Other Neuropsychiatric Symptoms.

Authors:  Joshua T Fuller; Tabina K Choudhury; Deborah A Lowe; Steve Balsis
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2020-10-16       Impact factor: 4.077

8.  Moderating risk of Alzheimer's disease through the use of anxiolytic agents.

Authors:  Shanna L Burke; Janice O'Driscoll; Amary Alcide; Tan Li
Journal:  Int J Geriatr Psychiatry       Date:  2016-11-02       Impact factor: 3.485

9.  Affective Neuropsychiatric Symptoms as Early Signs of Dementia Risk in Older Adults.

Authors:  Jung Yun Jang; Jean K Ho; Anna E Blanken; Shubir Dutt; Daniel A Nation
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Entorhinal Cortex Thickness across the Human Lifespan.

Authors:  Khader M Hasan; Benson Mwangi; Bo Cao; Zafer Keser; Nicholas J Tustison; Peter Kochunov; Richard E Frye; Mirjana Savatic; Jair Soares
Journal:  J Neuroimaging       Date:  2015-10-08       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.